AMGN — AMGEN INC

Nasdaq · Health Care · Biotechnology · CIK 318154 ·
Last close
$347.01
Market Cap
$187.28B
52W High
$358.46
52W Low
$318.12
ADV30
2,899,157
Next earnings
2026-08-04
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 8,618,000,000 5,874,000,000 2,666,000,000 1,819,000,000 92,504,000,000 12,038,000,000 83,314,000,000
Dec 2025 9,866,000,000 6,890,000,000 2,720,000,000 1,333,000,000 90,586,000,000 9,129,000,000 81,928,000,000
Sep 2025 9,557,000,000 6,475,000,000 2,526,000,000 3,216,000,000 90,141,000,000 9,445,000,000 80,522,000,000
Jun 2025 9,179,000,000 6,168,000,000 2,656,000,000 1,432,000,000 87,897,000,000 8,028,000,000 80,469,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$10,756,000,000
Investing CF
$-2,212,000,000
Financing CF
$-5,316,000,000
CapEx
$-2,159,000,000
Dividends Paid
$-5,203,000,000
Buybacks
EPS Diluted TTM
$14.37
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-24,650,000,000
Inventory
$6,186,000,000
Receivables
$9,138,000,000
ST Investments
EBIT TTM
$11,776,000,000
Pretax Income TTM
$9,087,000,000
Interest Exp TTM
$2,689,000,000
Analysts
30

Yahoo Snapshot (yfinance, live)

Total Revenue
$37,219,999,744
EBITDA
$16,917,999,616
Free Cash Flow
$7,436,624,896
Enterprise Value
$232,569,176,064
Total Cash
$12,037,999,616
Total Debt
$57,322,999,808
Shares Out
539,708,274
Trailing EPS
$14.37
Book Value
$17.03
ROE
101.3%
ROA
8.3%
Div Yield
2.90%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 36,751,000,000 9,080,000,000 7,711,000,000 90,586,000,000 81,928,000,000 9,958,000,000
Dec 2024 33,424,000,000 7,258,000,000 4,090,000,000 91,839,000,000 85,962,000,000 11,490,000,000
Dec 2023 28,190,000,000 7,897,000,000 6,717,000,000 97,154,000,000 90,922,000,000 8,471,000,000
Dec 2022 26,323,000,000 9,566,000,000 6,552,000,000 65,121,000,000 61,460,000,000 9,721,000,000

TTM Snapshot

Revenues TTM
$28,764,000,000
NetIncome TTM
$8,587,000,000
OpCashFlow TTM
$0
Assets (Latest)
$91,839,000,000
Forward EPS
$23.48

Max Pain — expiry 2026-06-26

max pain strike: $345.00 · spot: $351.43 · call oi: 3,799 · put oi: 2,584
Expected Move to 2026-06-26: ±$6.61 (1.88%) — implied range $344.82$358.03 · ATM straddle on $352.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GILD GILEAD SCIENCES, INC. $155.26B $125.05
ARGX ARGENX SE $53.07B $853.40
RVMD Revolution Medicines, Inc. $36.04B $169.51
BIIB BIOGEN INC. $29.11B $197.19
MRNA Moderna, Inc. $24.20B $61.00

News headlines (Yahoo Finance, 1h cache)

Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update
2026-06-24 13:27 · Yahoo
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-23 23:53 · Yahoo
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
2026-06-23 15:50 · Yahoo
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
2026-06-23 13:50 · Yahoo
2 Underrated Weight Loss Stocks to Buy and Hold
2026-06-23 07:05 · Yahoo
Willful Patent Infringement Verdict Might Change The Case For Investing In Amgen (AMGN)
2026-06-23 00:13 · Yahoo
Stock Market Today: Dow Up As Bessent Makes This Iran Move; SpaceX Craters (Live Coverage)
2026-06-22 20:31 · Yahoo
Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court
2026-06-22 19:47 · Yahoo
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
2026-06-19 17:10 · Yahoo
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
2026-06-19 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.